|
1
|
Palumbo A and Anderson K: Multiple
myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Terpos E, Morgan G, Dimopoulos MA, et al:
International Myeloma Working Group recommendations for the
treatment of multiple myeloma-related bone disease. J Clin Oncol.
31:2347–2357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Munshi NC and Anderson KC: New strategies
in the treatment of multiple myeloma. Clin Cancer Res.
19:3337–3344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rossi M, Di Martino MT, Morelli E, et al:
Molecular targets for the treatment of multiple myeloma. Curr
Cancer Drug Targets. 12:757–767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao Y, Gao F, Ma JL, Sun WZ and Song LP:
The potential clinical applications and prospects of microRNAs in
lung cancer. Onco Targets Ther. 7:901–906. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nana-Sinkam SP and Croce CM: Clinical
applications for microRNAs in cancer. Clin Pharmacol Ther.
93:98–104. 2013. View Article : Google Scholar
|
|
7
|
Rajkumar SV: Multiple myeloma: 2011 update
on diagnosis, risk-stratification, and management. Am J Hematol.
86:57–65. 2011. View Article : Google Scholar
|
|
8
|
Lionetti M, Agnelli L, Mosca L, et al:
Integrative high-resolution microarray analysis of human myeloma
cell lines reveals deregulated miRNA expression associated with
allelic imbalances and gene expression profiles. Genes Chromosomes
Cancer. 48:521–531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA, Sevignani C, Dumitru CD, et al:
Human microRNA genes are frequently located at fragile sites and
genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iorio MV and Croce CM: Causes and
consequences of microRNA dysregulation. Cancer J. 18:215–222. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tagliaferri P, Rossi M, Di Martino MT, et
al: Promises and challenges of MicroRNA-based treatment of multiple
myeloma. Curr Cancer Drug Targets. 12:838–846. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lionetti M, Biasiolo M, Agnelli L, et al:
Identification of microRNA expression patterns and definition of a
microRNA/mRNA regulatory network in distinct molecular groups of
multiple myeloma. Blood. 114:e20–e26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Calin GA and Croce CM: MicroRNA-cancer
connection: the beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chesi M and Bergsagel PL: Molecular
pathogenesis of multiple myeloma: basic and clinical updates. Int J
Hematol. 97:313–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Klein B, Seckinger A, Moehler T and Hose
D: Molecular pathogenesis of multiple myeloma: chromosomal
aberrations, changes in gene expression, cytokine networks, and the
bone marrow microenvironment. Recent Results Cancer Res. 183:39–86.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pichiorri F, Suh SS, Rocci A, et al:
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs
the p53/MDM2 autoregulatory loop in multiple myeloma development.
Cancer Cell. 18:367–381. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Noh JH, Chang YG, Kim MG, et al: MiR-145
functions as a tumor suppressor by directly targeting histone
deacetylase 2 in liver cancer. Cancer Lett. 335:455–462. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boufraqech M, Zhang L, Jain M, et al:
miR-145 suppresses thyroid cancer growth and metastasis and targets
AKT3. Endocr Relat Cancer. 21:517–531. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee SJ, Kim SJ, Seo HH, et al:
Over-expression of miR-145 enhances the effectiveness of HSVtk gene
therapy for malignant glioma. Cancer Lett. 320:72–80. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cho WC, Chow AS and Au JS: Restoration of
tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung
adenocarcinoma patients with epidermal growth factor receptor
mutation. Eur J Cancer. 45:2197–2206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chiyomaru T, Enokida H, Tatarano S, et al:
miR-145 and miR-133a function as tumour suppressors and directly
regulate FSCN1 expression in bladder cancer. Br J Cancer.
102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang J, Guo H, Zhang H, et al: Putative
tumor suppressor miR-145 inhibits colon cancer cell growth by
targeting oncogene Friend leukemia virus integration 1 gene.
Cancer. 117:86–95. 2011. View Article : Google Scholar
|
|
26
|
Spizzo R, Nicoloso MS, Lupini L, et al:
miR-145 participates with TP53 in a death-promoting regulatory loop
and targets estrogen receptor-alpha in human breast cancer cells.
Cell Death Differ. 17:246–254. 2010. View Article : Google Scholar
|
|
27
|
Lin Y, Peng S and Yu H: RNAi-mediated
downregulation of NOB1 suppresses the growth and colony-formation
ability of human ovarian cancer cells. Med Oncol. 29:311–317. 2012.
View Article : Google Scholar
|
|
28
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Manikandan J, Aarthi JJ, Kumar SD and
Pushparaj PN: Oncomirs: the potential role of non-coding microRNAs
in understanding cancer. Bioinformation. 2:330–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cordes KR, Sheehy NT, White MP, et al:
miR-145 and miR-143 regulate smooth muscle cell fate and
plasticity. Nature. 460:705–710. 2009.PubMed/NCBI
|
|
31
|
Ostenfeld MS, Bramsen JB, Lamy P, et al:
miR-145 induces caspase-dependent and -independent cell death in
urothelial cancer cell lines with targeting of an expression
signature present in Ta bladder tumors. Oncogene. 29:1073–1084.
2010. View Article : Google Scholar
|
|
32
|
Villadsen SB, Bramsen JB, Ostenfeld MS, et
al: The miR-143/-145 cluster regulates plasminogen activator
inhibitor-1 in bladder cancer. Br J Cancer. 106:366–374. 2012.
View Article : Google Scholar :
|
|
33
|
Xu N, Papagiannakopoulos T, Pan G, Thomson
JA and Kosik KS: MicroRNA-145 regulates OCT4, SOX2, and KLF4 and
represses pluripotency in human embryonic stem cells. Cell.
137:647–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sachdeva M, Zhu S, Wu F, et al: p53
represses c-Myc through induction of the tumor suppressor miR-145.
Proc Natl Acad Sci USA. 106:3207–3212. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shi B, Sepp-Lorenzino L, Prisco M, Linsley
P, deAngelis T and Baserga R: Micro RNA 145 targets the insulin
receptor substrate-1 and inhibits the growth of colon cancer cells.
J Biol Chem. 282:32582–32590. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sachdeva M and Mo YY: MicroRNA-145
suppresses cell invasion and metastasis by directly targeting mucin
1. Cancer Res. 70:378–387. 2010. View Article : Google Scholar :
|
|
37
|
Gregersen LH, Jacobsen AB, Frankel LB, Wen
J, Krogh A and Lund AH: MicroRNA-145 targets YES and STAT1 in colon
cancer cells. PLoS One. 5:e88362010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lu R, Ji Z, Li X, et al: miR-145 functions
as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in
renal cell carcinoma. J Cancer Res Clin Oncol. 140:387–397. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li E, Zhang J, Yuan T and Ma B: miR-145
inhibits osteosarcoma cells proliferation and invasion by targeting
ROCK1. Tumour Biol. 35:7645–7650. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xing AY, Wang B, Shi DB, et al:
Deregulated expression of miR-145 in manifold human cancer cells.
Exp Mol Pathol. 95:91–97. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Feng Y, Zhu J, Ou C, et al: MicroRNA-145
inhibits tumour growth and metastasis in colorectal cancer by
targeting fascin-1. Br J Cancer. 110:2300–2309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Y, Hu C, Cheng J, et al: MicroRNA-145
suppresses hepatocellular carcinoma by targeting IRS1 and its
downstream Akt signaling. Biochem Biophys Res Commun.
446:1255–1260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shao Y, Qu Y, Dang S, Yao B and Ji M:
MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by
targeting c-Myc and Cdk6. Cancer Cell Int. 13:512013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chandramohan V, Jeay S, Pianetti S and
Sonenshein GE: Reciprocal control of Forkhead box O 3a and c-Myc
via the phosphatidylinositol 3-kinase pathway coordinately
regulates p27Kip1 levels. J Immunol. 172:5522–5527. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cheng GZ, Park S, Shu S, et al: Advances
of AKT pathway in human oncogenesis and as a target for anti-cancer
drug discovery. Curr Cancer Drug Targets. 8:2–6. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Medema RH, Kops GJ, Bos JL and Burgering
BM: AFX-like Forkhead transcription factors mediate cell cycle
regulation by Ras and PKB through p27kip1. Nature. 404:782–787.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Roy SK, Srivastava RK and Shankar S:
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of
FOXO transcription factor, leading to cell cycle arrest and
apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Massague J: G1 cell-cycle control and
cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Maddika S, Ande SR, Panigrahi S, et al:
Cell survival, cell death and cell cycle pathways are
interconnected: implications for cancer therapy. Drug Resist Updat.
10:13–29. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Datta SR, Dudek H, Tao X, et al: Akt
phosphorylation of BAD couples survival signals to the
cell-intrinsic death machinery. Cell. 91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
